Literature DB >> 22612899

Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.

Carla Treloar1, Peter Hull, Gregory J Dore, Jason Grebely.   

Abstract

INTRODUCTION AND AIMS: Uptake of treatment for hepatitis C virus (HCV) infection among people who inject drugs is low. Further understanding is required of the relationship between HCV knowledge and treatment willingness, assessment and treatment in this population. DESIGN AND METHODS: A cross-sectional self-administered survey was conducted with clients of four opioid substitution therapy (OST) clinics and the Medically Supervised Injecting Centre in Sydney, Australia.
RESULTS: Of 132 participants, 85 (64%) self-reported having HCV infection. HCV knowledge was mixed (mean 6.5, range 0-12) and was relatively lower on items measuring knowledge of factors impacting HCV-related disease progression. The likelihood of being in a higher knowledge category was associated with being female [adjusted odds ratio (AOR) = 3.78, 95% confidence interval (CI) (1.79, 7.98)], higher formal education [AOR = 3.28, 95% CI (1.57, 6.88)], being on a current OST program [AOR = 2.61, 95% CI (1.10, 6.19)] and being older [AOR = 1.04, 95% CI (1.01, 1.09)]. Participants receiving OST were more likely to report higher willingness to have HCV treatment [OR = 4.45, 95% CI (2.23, 8.17)]. Having been assessed for HCV treatment was associated with younger age [AOR = 0.93; CI 95% (0.88, 1.00)] and higher formal education [AOR = 7.81; 95% CI (1.62, 37.71)]. DISCUSSION AND
CONCLUSIONS: Overall, knowledge scores were mid-range. Knowledge of modifiable factors influencing HCV-related liver disease progression was particularly low indicating the need for ongoing education. Education should also be targeted at older people and those not on OST, and be inclusive of those with lower literacy levels.
© 2012 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Mesh:

Year:  2012        PMID: 22612899     DOI: 10.1111/j.1465-3362.2012.00468.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  30 in total

1.  No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening.

Authors:  Brianna L Norton; William N Southern; Meredith Steinman; Bryce D Smith; Joseph Deluca; Zachary Rosner; Alain H Litwin
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-19       Impact factor: 11.382

2.  Knowledge of Hepatitis C Risk Factors is Lower in High Incidence Regions.

Authors:  Terry Knick; Jacqueline E Sherbuk; Rebecca Dillingham
Journal:  J Community Health       Date:  2019-02

3.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

4.  Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.

Authors:  Trena I Mukherjee; Veena Pillai; Siti Hafizah Ali; Frederick L Altice; Adeeba Kamarulzaman; Jeffrey A Wickersham
Journal:  Int J Drug Policy       Date:  2017-06-23

5.  Retention in buprenorphine treatment is associated with improved HCV care outcomes.

Authors:  B L Norton; A Beitin; M Glenn; J DeLuca; A H Litwin; C O Cunningham
Journal:  J Subst Abuse Treat       Date:  2017-01-27

6.  Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.

Authors:  Diana Hernández; Daniel J Feaster; Lauren Gooden; Antoine Douaihy; Raul Mandler; Sarah J Erickson; Tiffany Kyle; Louise Haynes; Robert Schwartz; Moupali Das; Lisa Metsch
Journal:  AIDS Behav       Date:  2016-01

7.  Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study.

Authors:  B L Norton; M A Bachhuber; R Singh; L Agyemang; J H Arnsten; C O Cunningham; A H Litwin
Journal:  Int J Drug Policy       Date:  2019-04-16

Review 8.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.

Authors:  Jason Grebely; Megan Oser; Lynn E Taylor; Gregory J Dore
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

9.  Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Authors:  Marija Zeremski; Rositsa B Dimova; Roberto Zavala; Steven Kritz; Melissa Lin; Bryce D Smith; Jon E Zibbell; Andrew H Talal
Journal:  J Addict Med       Date:  2014 Jul-Aug       Impact factor: 3.702

10.  Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

Authors:  Alain H Litwin; John Jost; Katherine Wagner; Moonseong Heo; Alison Karasz; Judith Feinberg; Arthur Y Kim; Paula J Lum; Shruti H Mehta; Lynn E Taylor; Judith I Tsui; Irene Pericot-Valverde; Kimberly Page
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.